Prognostic Significance of Circulating Tumor DNA in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.
Blood tests measuring tumor DNA reliably predict outcomes in advanced prostate cancer, supporting their use in routine care.
A systematic review and meta-analysis consolidating evidence on ctDNA as a prognostic biomarker in metastatic prostate cancer, supporting its role in predicting disease outcomes. These findings strengthen the evidence base for ctDNA implementation in prostate cancer management.
What the study was
- Study design
- Systematic review and meta-analysis
- Population
- Metastatic prostate cancer patients across included trials
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Clinical Genitourinary Cancer
Why it surfaced
Meta-analytic synthesis strengthens ctDNA evidence base in metastatic prostate cancer; standard addition for liquid biopsy surveillance.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.